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Papers
Population based randomised controlled trial on impact of
screening on mortality from abdominal aortic aneurysm
Paul E Norman, Konrad Jamrozik, Michael M Lawrence-Brown, Max T Q Le, Carole A Spencer, Raywin J Tuohy,
Richard W Parsons, James A Dickinson
Abstract
Objective To assess whether screening for abdominal aortic
aneurysms in men reduces mortality.
Design Population based randomised controlled trial of
ultrasound screening, with intention to treat analysis of age
standardised mortality.
Setting Community based screening programme in Western
Australia.
Participants 41 000 men aged 65-83 years randomised to
intervention and control groups.
Intervention Invitation to ultrasound screening.
Main outcome measure Deaths from abdominal aortic
aneurysm in the five years after the start of screening.
Results The corrected response to invitation to screening was
70%. The crude prevalence was 7.2% for aortic diameter ≥ 30
mm and 0.5% for diameter ≥ 55 mm. Twice as many men in the
intervention group than in the control group underwent
elective surgery for abdominal aortic aneurysm (107 v 54,
P = 0.002, 2 test). Between scheduled screening and the end of
follow up 18 men in the intervention group and 25 in the
control group died from abdominal aortic aneurysm, yielding a
mortality ratio of 0.61 (95% confidence interval 0.33 to 1.11).
Any benefit was almost entirely in men aged between 65 and 75
years, where the ratio was reduced to 0.19 (0.04 to 0.89).
Conclusions At a whole population level screening for
abdominal aortic aneurysms was not effective in men aged
65-83 years and did not reduce overall death rates. The success
of screening depends on choice of target age group and the
exclusion of ineligible men. It is also important to assess the
current rate of elective surgery for abdominal aortic aneurysm
as in some communities this may already approach a level that
reduces the potential benefit of population based screening.
Introduction
Despite advances in vascular surgery and intensive care, the
overall case fatality of rupture of an abdominal aortic aneurysm
is still around 80%.1 In addition, the incidence of such events
seems to have risen over the past two decades.2–4 This contrasts
with trends seen in coronary heart disease and stroke, suggesting
that measures introduced to reduce the impact of occlusive arte-
rial disease have not been effective.
The feasibility of population based screening for such aneu-
rysms by using ultrasound has been established over the past 15
years.5–7 These early studies generated considerable debate about
the merits of population screening, resulting in calls for
randomised controlled trials.8–10 In the first such trial, Scott et al
reported a large (50%) but non-significant reduction in mortality
with screening.11 Since then two randomised trials and several
non-randomised studies have all indicated that screening in men
saves lives cost effectively.12–16 We designed a trial to complement
these, focusing on men aged 65 to 74 years but also including an
older group.
The Western Australia trial of screening for abdominal aortic
aneurysms is a population based randomised controlled trial to
determine whether a single ultrasound screen for abdominal
aortic aneurysms17 reduces deaths among those to whom it is
offered. The trial was designed to cover an entire metropolitan
community and assess the effectiveness of introducing
population screening into an existing healthcare system.Western
Australia is an ideal location for such a trial: the population is
geographically isolated and stable, all deaths and hospital admis-
sions are linked within a unified database system, and much is
already known about local trends and outcomes for abdominal
aortic aneurysm.1 3 18 19 Here we report on the early effect of
screening on mortality in the trial.
Methods
Study population
To provide the most rigorous possible test of the utility of
screening, we designed the trial as a population based study with
the primary end point, mortality from abdominal aortic
aneurysm, to be analysed on an intention to treat basis. We
planned to have 90% power to detect and declare significant (two
sided = 0.05) a relative reduction of 50% in mortality among
men invited for screening over five years from the start of
screening. Using available pilot data, we estimated that the
control group would need to contain about 20 000 men to expe-
rience 55 deaths from abdominal aortic aneurysm.3
Men were identified from an electronic copy of the electoral
roll, enrolment to vote being compulsory for all Australian
adults. The ideal target age range for screening is 65-74 years, but
the electoral roll listed fewer than 40 000 men in this age group
in the main metropolitan area of Perth (the capital city of West-
ern Australia) and satellite towns. The addition of men aged
75-79 years increased the potentially available number to about
50 000. We excluded 8801 because they lived in the furthest sat-
ellite town (about 35 km away from Perth), and we did not have
the resources to set up a screening clinic in this location. We
achieved our required sample size without including them.
At the beginning of the trial we selected all 41 000 men on
the electoral roll who were resident in Perth and were expected
to be 65-79 years old at the projected mid-point of screening.
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Men were randomised into intervention and control groups of
equal size defined by five year age group and postcode. Men in
the control group were allocated a “virtual” date of screening,
which was the median scheduled date of examination for men
from the same postcode area randomised to the intervention
group. Men in the intervention group were sent a letter explain-
ing the study and an appointment for a scan. Men who did not
take up the initial invitation to screening were sent a second let-
ter.
At the five screening clinics the greatest transverse and
anteroposterior diameter was measured with a Toshiba Capasee
ultrasound machine with a 3.75 MHz probe (Toshiba Australia,
North Ryde, NSW). On leaving the clinic, each man was given a
letter containing the results of his scan, with a copy for his gen-
eral practitioner. The general practitioner arranged any follow
up investigations or referral to a surgeon.Wemade no attempt to
influence any aspects of clinical management, in particular with
regards to threshold for intervention or method of repair.
Procedures for follow up
We used electronic record linkage to population based named
identified records for deaths and admissions to hospital in West-
ern Australia to identify end points in the target population.
When linkage to a death registration was confirmed, a researcher
who was unaware of group allocation coded up to four causes of
death from the text of the original death certificate. Deaths with
mention of abdominal aortic aneurysm were identified for
further blinded independent confirmation of the contribution to
death of the aneurysm or surgery for the aneurysm.We also used
electronic record linkage to identify all men undergoing surgery
for abdominal aortic aneurysm, either before or after scheduled
screening. For admission dates before 1988 we used a combina-
tion of international classification of disease, ninth revision,
(ICD-9) diagnosis codes (441.30 or 441.40) and International
Classification for Procedures in Medicine (ICPM) code (58.53).
Patients admitted from 1988 to 31 June 1999 were identified
with the combined ICD-9 clinical modification (ICD-9-CM)
diagnosis codes (441.30 or 441.40) and ICD-9-CM procedure
code (38.44). Patients admitted after 1 July 1999 were identified
with ICD-10 codes (I71.3 or I71.4).
Statistical methods
We initially compared crude and age standardised mortality
from definite abdominal aortic aneurysm in the two groups
between each man’s actual or virtual date of screening and the
end of follow up on 31March 2001, which was five years after the
trial began. Principal results are presented as ratios and
corresponding 95% confidence intervals for mortality for
abdominal aortic aneurysm adjusted in single year strata to the
age structure of the male population of Western Australia. To
facilitate comparison with studies such as the multicentre aneu-
rysm screening study (MASS),15 our secondary analyses included
the mortality rate ratio for deaths from abdominal aortic
aneurysm in men aged 64-75 years. Finally, we examined
mortality from all causes over the five years of the programme.
Results
Figure 1 shows the flow of participants through the study. The
41 000 men randomised to the two groups were balanced for
age (mean (SD) 72.6 (4.7) v 72.6 (4.7) years). Screening was com-
pleted over a period of 32 months, and the median follow up was
43 (range 27-61) months. Because of the method of recording
age in the electoral roll, some men were older than the target age
range by the time they were invited for screening and, as a result,
725 (5.9%) of those who attended were aged 80-83 years.17
Potentially eligible men (n=49 801)
Not randomised
(lived too far away) (n=8801)
Died before invitation (n=2296)
Did not attend/refused (n=5303)
Could not be scanned (n=10)
Ineligible:
 Away (n=238)
 Previous scan or operation for
  abdominal aortic aneurysm (n=328)
 Too sick (n=609)
 Invitations returned to sender (n=543)
 Should not have been invited (n=118)
Randomised (1 April 1996) (n=41 000)
Invited
(n=19 352)
Death registry
Hospital registry for operations for aortic aneurysm
Control
(n=19 352)
Virtual
scan date
Valid scans
(n=12 203)
Abdominal  aortic
aneurysm (n=875)
Abdominal  aortic
aneurysm surgery
during trial (n=86)
No abdominal  aortic
aneurysm (n=11 328)
Fig 1 Summary of trial of screening for abdominal aortic aneurysm
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Participation in screening and prevalence of abdominal
aortic aneurysm
There was no difference between the numbers of men in the two
groups who had had surgery for abdominal aortic aneurysm
before scheduled screening (table 1, P = 0.47, 2test). Within the
men invited for screening, the prevalence of previous surgery for
abdominal aortic aneurysm was highest among those who did
not attend (2.7%). Similar numbers of men in the two groups
died between randomisation and scheduled screening, including
25 deaths from rupture (13 in invited group, 12 in control
group). After correcting the lists for deaths, we sent letters of
invitation to 19 352 men. Of these, 12 213 underwent a
screening examination, a crude response fraction of 63.1%. If we
excluded 1836 men who would generally be considered ineligi-
ble this figure increased to 70% (fig 1).
The overall crude prevalence of any aortic aneurysms (aorta
≥ 30 mm) was 7.2%, increasing from 4.8% in men aged 65-69
years to 10.8% in the oldest men. Of the 875 cases detected, 699
(80%) aortas were 30-44 mm in diameter, 115 (13%) were 45-54
mm in diameter, and 61 (7%) were ≥ 55 mm in diameter.17
Procedures and deaths after scheduled screening
Table 2 shows the numbers of procedures for and deaths from
abdominal aortic aneurysm after scheduled screening. Table 3
shows the corresponding numbers of events that occurred
between randomisation and the end of follow up. The overall
mortality within 30 days was 4.3% (7/161) after elective surgery
and 24% (4/17) after surgery for ruptured aneurysms (table 2),
with no difference between study groups (P = 0.59, 2 test). Twice
as many men in the intervention group underwent elective sur-
gery for abdominal aortic aneurysm compared with the number
in the control group (107 v 54, P = 0.002, 2 test).
Between scheduled screening and the end of follow up 18
men died from abdominal aortic aneurysm in the intervention
group and 25 in the control group (table 2), yielding a mortality
rate ratio of 0.61 (95% confidence interval 0.33 to 1.11). The age
standardised mortality for those who actually attended screening
was 60% lower than in the control group (7.48 v 18.91 deaths per
100 000 man years, table 2). Between randomisation and the end
of follow up there were 31 deaths from abdominal aortic
aneurysm in the intervention group and 37 in the control group,
yielding a mortality rate ratio of 0.85 (0.53 to 1.36, table 3).
Figures 2 and 3 show the cumulative mortality from abdominal
aortic aneurysm. Men in the intervention group initially had a
higher mortality, but after one year the mortality curves crossed,
such that the difference between them was not significant.
Table 4 summarises the mortality from abdominal aortic
aneurysm in men aged 65-74 years and ≥ 75 years. There were
no deaths among men aged 65-74 years who underwent screen-
ing and only two deaths (after scheduled screening) among those
who were invited but did not attend compared with 10 in the
Table 1 Elective and emergency procedures for abdominal aortic aneurysm
before scheduled screening
Group Elective* Emergency Total (%)
Scanned (n=12 203) 20 2 22 (0.2)
Not scanned (n=8 297) 198 29 227 (2.7)
Total invited (n=19 352) 218 31 249 (1.3)
Control (n=19 352) 191 33 224 (1.2)
*Includes emergency symptomatic cases.
Table 2 Elective and emergency procedures and crude and age standardised mortality from abdominal aortic aneurysm between scheduled screening and the
end of follow up
Elective Emergency
Total deaths (%)
Age standardised
mortality* (95% CI)Operation
Postoperative
death (%) All ruptures Operation
Postoperative
death
Fatal rupture without
surgery
Intervention group
Scanned (n=12 203) 86 4 (4.7) 3 0 0 3 7 (0.06) 7.48 (1.91 to 13.05)
Not scanned (n=7 149) 21 0 30 9 1 10 11 (0.15) 18.27 (7.08 to 29.46)
Total invited (n=19 352) 107 4 (3.7) 33 9 1 13 18 (0.09) 11.51 (6.16 to 16.86)
Control group
Total (n=19 352) 54 3 (5.6) 38 8 3 19 25 (0.13) 18.91 (10.97 to 26.85)
*Age standardised per 100 000 in strata of one year to age structure of Western Australian male population aged 65-83 years.
Table 3 Elective and emergency procedures, deaths, and crude and age standardised mortality from abdominal aortic aneurysm between randomisation and
the end of follow up
Elective Emergency
Total deaths (%)
Age standardised
mortality* (95% CI)Operation
Postoperative
death (%) All ruptures Operation
Postoperative
death
Fatal rupture without
surgery
Intervention group
Scanned (n=12 203) 86 4 (4.7) 3 0 0 3 7 (0.06) 7.48 (1.91 to 13.05)
Not scanned (n=8 297) 26 1 (3.9) 35 11 2 21 24 (0.29) 46.56 (24.7 to 68.4)
Total invited (n=20 500) 112 5 (4.5) 38 11 2 24 31 (0.15) 23.55 (13.79 to 33.31)
Control group
Total (n=20 500) 60 4 (6.7) 41 10 5 28 37 (0.18) 27.83 (16.89 to 38.77)
*Age standardised per 100 000 in strata of one year to age structure of Western Australian male population aged 65-83 years.
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Fig 2 Cumulative mortality due to abdominal aortic aneurysm after date of
screening
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control group, an odds ratio of 0.19 (0.04 to 0.89, P = 0.01).
When we included deaths between randomisation and
scheduled screening, however, we found no benefit in the
younger age group (odds ratio 0.82, 0.37 to 1.84, P = 0.6).
Table 5 and figures 4 and 5 show the cumulative and age
standardised all cause mortality. There is clear evidence of
response bias among men who took up the invitation to be
screened; their mortality experience was close to half that of
invited men who did not undergo a scan. Overall, however, there
were no meaningful differences in the age standardised mortal-
ity rates for all causes for the invited and control groups.
Discussion
The main conclusion from our population based randomised
controlled trial of ultrasound screening for abdominal aortic
aneurysm in Western Australia is that associated mortality for
men aged 65-83 years is not significantly reduced by a screening
programme. Although there was substantial benefit for the men
who attended for screening, the overall benefit was reduced by
deaths among men who did not attend. The multicentre
aneurysm screening study (MASS) has already provided
convincing evidence that screening men aged 65-74 years has
the potential to reduce the mortality.15 In light of these findings,
a target group aged 65-74 years may have been more suitable for
our study. Indeed, subgroup analysis indicated that this group
benefited the most from screening. For several reasons, however,
we had to include 13 688 (33.4%) men aged 75-83 years. These
men cannot be excluded post hoc and our primary intention to
treat analysis included all randomised men aged 65-83 years.
Method of recruitment
In addition to the differences in target age range, our trial and
the multicentre study used quite different methods of
recruitment (electoral roll and general practice lists). As system-
atic screening is often based on centralised population databases
rather than general practice lists, our trial is probably more rep-
resentative of what would occur in many countries if screening
were to be introduced. Because we used a centralised database,
however, we could not exclude various categories of “ineligible”
men before randomisation (fig 1). Thus we included men who
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Fig 3 Cumulative mortality due to abdominal aortic aneurysm after date of
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Table 4 Cumulative mortality from abdominal aortic aneurysm in men aged 64-75 years and ≥75 years
65-74 years ≥75 years
No of men (person years) Deaths No of men (person years) Deaths
From randomisation
Intervention group:
Scanned 8 641 (30 462) 0 3 562 (13 011) 7
Not scanned 5 200 (17 876) 11 3 097 (10 746) 13
Total invited 13 841 (48 338) 11 6 659 (23 757) 20
Control group 13 464 (46 912) 13 7 036 (25 046) 24
Odds ratio (95% CI) 0.82 (0.37 to 1.84) 0.88 (0.49 to 1.6)
From scheduled screening
Intervention group:
Scanned 8 641 (30 462) 0 3 562 (13 011) 7
Not scanned 4 657 (16 104) 2 2 492 (8 743) 9
Total invited 13 298 (46 566) 2 6 054 (21 754) 16
Control group 12 938 (45 177) 10 6 414 (22 949) 15
Odds ratio (95% CI) 0.19 (0.04 to 0.89) 1.13 (0.56 to 2.29)
Table 5 Cumulative and age standardised all cause mortality over five years after real or virtual date of screening
Subgroup of men No of men Person years Cumulative deaths (%) Age standardised mortality* (95% CI)
Scanned 12 203 43 473 1071 (8.8) 1501 (1377 to 1625)
Not scanned 7 149 24 847 1161 (16.2) 2885 (2691 to 3079)
Total invited 19 352 68 320 2232 (11.5) 1976 (1945 to 2117)
Control 19 352 68 126 2571 (13.3) 2020 (1948 to 2092)
Non-randomised men 8 801 29 067 1166 (13.2) 2238 (2075 to 2401)
Overall total 47 505 165 513 5949 (12.5) 2112 (2041 to 2184)
*Age standardised per 100 000 in strata of one year to age structure of Western Australian male population aged 65-83 years.
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were not randomised into the multicentre study (through being
too old, too ill, or resident in a nursing home). The exclusion of
such men optimises the effectiveness of screening by increasing
the level of participation. It also removes a group with a relatively
high incidence of ruptured abdominal aortic aneurysm. When
we applied the criteria for eligibility used in the multicentre study
to our study, the response fraction is about 70%. Although
attendance fell with increasing age,17 the lower response seen in
our trial was not simply due to inclusion of older men;
attendance in men aged 65-74 years was 74% compared with the
80% achieved in the multicentre study.15 It is possible that men
are more likely to participate if they are invited by their general
practitioner rather than a research group.
The mortality from abdominal aortic aneurysm was high in
the group of men who were invited but did not attend for
screening (table 2). The multicentre study investigators were able
to minimise the size of this group by exclusion before randomi-
sation. Strict criteria for considering an individual as “ineligible
for screening”may be easier for a general practitioner to apply in
the setting of a randomised controlled trial than in real life. A
proportion of patients with “other serious health problems” (an
exclusion criterion in the multicentre study) will die from
ruptured abdominal aortic aneurysm and may have benefited
from elective surgery—especially if stenting proves to be more
suitable than open repair in high risk cases.
Low mortality from abdominal aortic aneurysm in the
control group
Although our sample size calculation was based on published
rates of mortality in Western Australia,3 mortality from abdomi-
nal aortic aneurysm in our control group was lower than
expected (37 v 55 deaths). It was also lower than that seen in the
multicentre study. The crude cumulative all cause mortality in
the control group at four years was similar (12%) in both studies.
In contrast, the crude cumulative mortality from abdominal aor-
tic aneurysm in the control group was 0.33% in the multicentre
study and, despite inclusion of older men, only 0.11% in our
study. Contamination of our control group through ad hoc
screening during the trial period may have resulted in the diag-
nosis and successful treatment of some abdominal aortic
aneurysm in this group.More notably, however, linkage to hospi-
tal morbidity records showed that a surprisingly large
proportion (1%) of all randomised men had already had elective
surgery for an abdominal aortic aneurysm (table 1). This is sub-
stantially greater than in the multicentre study, where the preva-
lence of survivors of surgery for abdominal aortic aneurysm
seemed to be 0.26%. The high frequency of previous surgery in
Western Australia may be due to a higher incidence of abdomi-
nal aortic aneurysm or greater rates of diagnosis and treatment
before screening.
While the overall prevalence of any aneurysm (aortic
diameter ≥ 30 mm) was higher in our study than in the
multicentre study (7.2% v 4.9%), the proportion of the largest
aortas ( ≥ 55 mm in diameter) in Western Australia was almost
half that seen in the multicentre study (7% v 12%). As the preva-
lence of large aortas increases with age, this difference is even
more remarkable considering the greater age of our cohort. We
can only speculate about the reasons for these differences. One
possibility is the longstanding and easy availability of imaging
(ultrasound and computed tomography) to general practitioners
in Australia. This may have resulted in a relatively high level of
incidental detection and treatment of large aortas over the past
two decades. This aspect of a healthcare system needs to be taken
into account when screening for abdominal aortic aneurysm is
considered.
Deaths between randomisation and screening
In our trial, all men were randomised at the beginning of the
screening period and inevitably there were deaths from abdomi-
nal aortic aneurysm between randomisation and the date of
screening. These deaths were not included in our primary analy-
sis and they did not occur in the multicentre study as randomisa-
tion was undertaken as the trial progressed. In an ideal world
there should be no delay between becoming eligible for screen-
ing and actual screening, although in practice this may be a
problem.
The chief reasons for our overall result seem to be our failure
to identify and exclude men who were unlikely to attend and
may have been ineligible for surgery had they attended and a
high background level of detection and treatment of abdominal
aortic aneurysms in the study community. The success of screen-
ing will depend on choosing the best target age group (probably
men aged 65-74 years), excluding ineligible men, and
minimising delay between becoming eligible for screening and
actual screening. It is also important to assess the current rate of
elective surgery as in some communities this may already
approach a level that reduces the potential benefit of population
based screening.
We thank all the men who participated and all the partners who
encouraged them to participate. We also thank the State Electoral Commis-
sion, the Australian Bureau of Statistics, the registrar general of births,
deaths, and marriages, the Health Department of Western Australia, the
Time since randomisation (years)
Cu
m
ul
at
iv
e 
m
or
ta
lit
y 
(%
)
20 500
20 500
Control
Invited
No at risk
19 490
19 347
18 791
18 651
18 012
18 064
17 243
17 447
16 429
16 854
0
5
10
15
20
25
0 1 2 3 4 5
Control
Intervention
Fig 5 Cumulative all cause mortality from date of randomisation
What is already known on this topic
A screening programme for 65-74 year old men identified
as eligible by their general practitioners reduces mortality
from abdominal aortic aneurysm.
Such a screening programme is likely to be cost effective.
What this study adds
A screening programme for all 65-83 year old men does
not reduce mortality from abdominal aortic aneurysm.
Men aged 65-74 years may benefit from screening provided
there are no deaths between recruitment and actual
screening
A high background rate of diagnosis and successful
treatment may reduce the magnitude of benefit
In men aged 65-83 years less than 1% of all deaths are due
to abdominal aortic aneurysm
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participants’ general practitioners, and the hospitals in Perth for providing
space in which to conduct screening. Other people associated with the pro-
gramme were Yvonne Allen, Ann Blakemore, Michelle England, Lorili
Jacobs, Gill Kaye, Janet Mitchell, Carol Pearce, Lisa Rich, Lyn Schofield, Jan
Sleith, Teresa Warner, and Raylene Williamson. We thank the multicentre
aneurysm screening study investigators for their help, especially Alan Scott
for advice and encouragement and Theresa Marteau and Jane Colehan,
who facilitated use of their quality of life instrument. A final special thanks
and dedication goes to Bill Castleden.
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infarction with subsequent disability far more impor-
tant than a short admission for acute coronary
syndrome with rapid return to previous function.
The answers to the other two questions are also
negative. Hospital admissions occurred far more
frequently than the two more important events (table).
Biological rationale fails to support a presumption that
the invasive strategy will have similar effects on all three
end points. Indeed, the investigators explicitly state that
they expect an increase in short term deaths with sur-
gery, while achieving benefits in terms of decreased
angina and associated hospital admissions. The trend
toward increased deaths, with a large reduction in
admissions, with the invasive strategy provides support
for this hypothesis. The composite end point thus fails
all three criteria and provides little useful information
for clinical decision making.
Conclusions
The widespread use of composite end points reflects
their elegant simplicity as a solution to the problem of
declining event rates. Unfortunately, use of composite
end points makes the interpretation of the results of
randomised trials for clinical decision making
challenging. Investigators and their sponsors may
claim treatment effects over a broad range of
outcomes, whereas the effect may in fact be limited
to one component. Occasionally, composite end
points prove useful and informative for clinical
decision making. Often, they do not. These users’
guides will help clinicians differentiate between these
situations.
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Summary points
Composite end points are outcomes that capture
the number of patients experiencing one or more
of several adverse events
The validity of composite end points depends
on similarity in patient importance, treatment
effect, and number of events across the
components
When large variations exist between
components the composite end point should be
abandoned
Corrections and clarifications
Population based randomised controlled trial on impact
of screening on mortality from abdominal aortic
aneurysm
Tables 2 and 3 of both the abridged and the full
versions of this paper by Paul E Norman and
colleagues contain some incorrect values (BMJ
2004;329:1259-62). In table 2, for the emergency
procedures the “all ruptures” values are 19 and 22
for the “not scanned” and “total invited” groups
respectively and 27 in the control group; in table 3,
the corresponding values are 32, 35, and 38. The
authors state, however, that this amendment does
not alter their analyses or conclusions.
Risk of ischaemic stroke in people with migraine:
systematic review and meta-analysis of observational
studies
In our haste to correct this paper by Etminan and
colleagues (BMJ 2005;330:63-5, 8 Jan), some of the
authors’ late corrections were not carried out
properly—either at proof stage of the abridged
print version or in the correction that we
subsequently published on the web relating to the
full version only. In the abridged version, the
relative risk for migraine with aura in table 2
should be 2.88 (not 2.28); in table 1, the upper
confidence limit for migraine with aura for
Schwaag should be 3.53 (not 3.35), and the
cases:controls for the Collaborative Group should
be 430:151 (not 430:451). In the results section of
the full version, the references for the data on
migraine with and without aura are numbers 2, 3,
12-14, 17-19; in table 1, the cases:controls with
migraine is 26:26 for Donaghy (not for Chang as
stated in the previous correction).
Minerva
The eighth Minerva item (about a study published
in Neurology) in the issue of 22 January (BMJ
2005;330:204) may have misled readers by
including as its first sentence: “Survival in patients
with Parkinson’s disease is less than in the general
population.” This statement applies generally and is
contradictory to the actual finding of the study,
which is presented in the rest of the item. We
should and could have made it clearer that the first
statement was intended, as in most Minerva items,
as background.
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